The evaluation of gallstone formation in patients undergoing Roux-en -Y gastric bypass due to morbid obesity

Abstract

Objective: This study aimed to evaluate gallstone formation, prophylactic and selective cholecystectomy and the effectiveness of ursodeoxycholic acid treatment following laparoscopic Roux-en -Y gastric bypass (LRYGB) in morbid obese patients.
Material and Methods: Files of 60 patients who underwent LRYGB between October 2006 and March 2011 were retrospectively reviewed. Patients were evaluated for formation of gallstones.
Results: Fifty-three (88.3%) patients were female and seven (11.7%) were male. Eight of the 60 patients (13.3%) had previously undergone cholecystectomy. Six patients (11.5%) underwent cholecystectomy in addition to LRYGB due to preoperatively detected gallstones by ultrasonography. The remaining 46 patients were followed up for a mean duration of 28.57 months (5-56 months). In 10 (21.7%) of these patients, gallstones were detected and five patients with symptomatic gallstones underwent cholecystectomy. Patients who did and did not develop gallstones after LRYGB did not show a significant difference regarding age, gender and the new body mass index (BMI). Three patients were started on ursodeoxycholic acid and the treatment was continued for six months. Gallstones were not detected in these patients.
Conclusion: In light of these data, since only a very small portion of patients develops symptomatic gallstones after LRYGB, we recommend cholecystectomy in patients with symptomatic gallstones or the use of ursodeoxycholic acid rather than a prophylactic approach. Prospective randomized controlled studies in larger series are required to support these results.

Keywords: Obesity, laparoscopic gastric bypass, gallstones

Introduction

Obesity is a serious disease that has significant morbidity and mortality, and complex genetic and environmental etiologies (1). It can lead to hypertension, hyperlipidemia, cardiomyopathy, diabetes, hypoventilation disorders, increased risk of malignancy, cholelithiasis, degenerative arthritis, infertility and psychosocial disorders (2).

Following bariatric surgery, especially Roux-en-Y gastric bypass (RYGB), the frequency of gallstone formation increases as compared to the normal population due to rapid weight loss (3, 4). Hepatic supersaturation of bile with cholesterol, gallbladder stasis, and increased concentration of mucin within bile are possible causes (5).

Management of gallstone disease in these patients is still controversial and several therapeutic modalities are being used. These are performing cholecystectomy simultaneously with gastric bypass regardless of the presence of gallstones (prophylactic approach) (6-8), performing simultaneous cholecystectomy in all patients with gallstones (elective or selective approach) (9, 10), performing simultaneous cholecystectomy in patients with symptomatic gallstones, and methods in which prophylactic ursodeoxycholic acid (UDCA) therapy was initiated or not until development of symptoms (conventional approach) (5, 11).

We aimed to evaluate gallstone formation, prophylactic and selective cholecystectomy, and the effectiveness of ursodeoxycholic acid treatment following laparoscopic Roux-en-Y gastric bypass (LRYGB) in morbid obese patients.

Material and Methods

A retrospective chart review of 60 patients who underwent LRYGB between October 2006 and March 2011 was performed.

All patients received perioperative 2 gr. intravenous cefazolin for two days, and low molecular weight heparin was administered for ten days. Before induction of anesthesia, intermittent compression units were applied to both lower extremities.
The patients were called for outpatient follow-up at the end of 1 month and every 3 months for the first 2 years, and every 6 months in subsequent years. Changes in weight, blood count, calcium, iron binding, ferritin, vitamin B12 levels were examined and the necessary treatment changes were made.

Cholecystectomy was performed simultaneously during LRYGB in patients who were detected to have gallstones preoperatively. All remaining patients underwent abdominal ultrasonography during routine controls for presence of gallstones. Laparoscopic cholecystectomy was performed in patients with symptomatic gallstones. The remaining patients were followed up. Our approach to obesity and gallstones are summarized in Figure 1. An ethics committee approval was obtained from Tepecik Training and Research Hospital Ethics Committee, in 2011.

Figure 1. Flow-chart in obesity and gallstones LC: laparoscopic cholecystectomy; LRYGB: laparoscopic Roux-en-Y gastric by-pass; US: ultrasonography

Results

The majority of patients (n=53) were female, with a mean age of 41.17±11.09 years, and mean body mass index (BMI) of 47.79±6.98 kg/m2.

Eight of the 60 patients (13.3%) had a history of previous cholecystectomy. All of these patients were women. In 6 out of the remaining 52 patients (11.5%), who were also all women, gallstones was detected in the preoperative ultrasonography and they underwent cholecystectomy during LRYGB. The mean follow-up period of the remaining 46 patients was 28.57 months (5-56 months). During follow-up controls, all patients received an abdominal ultrasonography for the presence of gallstones. Gallstones were detected in 10 of these patients (21.7%) and only one of these patients was male.

The mean age of patients without gallstones on control ultrasonographies was 39.0±10.8 years, while that of patients with stones was 39.4±7.1 years and there was no statistically significant difference between them (p=0.912). The BMI of patients who had gallstones was found as 31.61 kg/m2 at the time of diagnosis, and the BMI of patients without gallstones was 30.61 kg/m2. There was no statistically significant difference between these two groups (p=0.595).

Ursodeoxycholic acid (UDCA) was applied in the last three patients after LRYGB, and was continued up to 6 months. Gallstones were not detected in these patients.

Six patients were diagnosed with cholelithiasis during evaluation of various complaints outside their routine controls. Five of them underwent laparoscopic cholecystectomy due to symptomatic gallstones. In four more patients within the remaining 40 group of patients, gallstones were detected by abdominal ultrasonography during a routine control. These patients were followed up because they were not symptomatic.

The gallstones were detected during the first 12 months in one patient, during the second 12 months in 8 patients and after 24 months in one patient. Gallstone detection during the second postoperative year was statistically significant (p<0.001).

Discussion

Obesity is becoming increasingly common in our country as in the rest of the world. In addition to increased frequency of various other diseases, obese patients have increased frequency of gallstones compared to the normal population (21-33%). The increase in the secretion of cholesterol by the liver and the reduced contractility of the gallbladder due to the increased cholesterol concentration without a proportional increase in phospholipids and bile salts play an important role in the formation of gallstones (12-14).

The surgical treatment of obesity not only provides weight loss but also significant improvement in co-morbid diseases (15). However, after surgery, especially after RYGB, gallstone formation also increases due to diet and rapid weight loss. This appears to be especially due to hepatic supersaturation of bile with cholesterol, gallbladder stasis, and increased concentration of mucin within bile (5).

The incidence of gallstones in morbidly obese patients varies between 21-33% and about 50% of them undergo cholecystectomy prior to bariatric surgery (6, 7, 16-19). In our patient group, gallstones were present in 14 of 60 patients (23.3%), and eight of them (57.1%) had undergone cholecystectomy previously.

No significant difference was found between patients who developed gallstones versus who did not after LRYGB, in terms of age, gender or new BMI. Although it is stated that the demographic characteristics do not effect gallstone formation (3), there are studies indicating that there is a significant increase in gallstone formation in women after RYGB as compared to men (20).

According to the literature, the risk of gallstones and/or the risk of symptomatic gallstone disease after bariatric surgery vary. In a population-based study conducted in Sweden, it was found that the risk of gallstone disease and cholecystitis after bariatric surgery is 5.5 times higher than the general population (4). Iglezias Brando de Oliviera et al. (3) have reported the incidence of gallstones after RYGB as 52.8%. Patel et al. (21) stated the rate of symptomatic gallstone disease requiring surgery after LRYGB as 6%. In our study, the incidence of gallstone disease after LRYGB was 21.7%, and the incidence of symptomatic gallstone disease was 10.9%. Out of 5 symptomatic patients, one developed acute pancreatitis, and two experienced acute cholecystitis. In the other two cases, there were biliary colic symptoms. All symptomatic patients underwent laparoscopic cholecystectomy.

The risk of developing gallstones during weight loss after bariatric surgery is increased. The risk is at the maximum level during rapid weight loss and around 24 months, and decreases to a minimum once the weight has stabilized (22). Our results were also consistent with the literature, gallstones were mainly identified within the first 24 months.

Ursodeoxycholic acid is a bile acid that reduces cholesterol saturation of bile by reducing cholesterol secretion. It also acts by decreasing the biliary nidus forming factors by reduction of glycoprotein secretion and dissolution of gallstones (11). A meta-analysis concluded that the daily administration of 500 mg UDCA is an effective method of preventing gallstone formation after bariatric surgery (11). A meta-analysis focusing on the side effects of UDCA treatment after bariatric surgery has not been published so far. However, it is stated that mild to moderate side effects are observed in most of the patients who use UDCA (22-24). UDCA was applied in the last three patients after LRYGB in our study and none developed gallstones. There were no side effects. However, it is not possible to make a conclusion due to the limited number of patients and the short follow-up period of these last patients.

Management of gallstone disease in these patients is still controversial and several therapeutic modalities are being used. These are performing cholecystectomy simultaneously with gastric bypass regardless of the presence of gallstones (prophylactic approach) (6-8), performing simultaneous cholecystectomy in all patients with gallstones (elective or selective approach) (9, 10), performing simultaneous cholecystectomy in patients with symptomatic gallstones, and methods in which prophylactic UDCA therapy was initiated or not until development of symptoms (conventional approach) (5, 11). The selective approach was preferred in our study.

The limitations of our study are the retrospective design of the study, the insufficient number of patients treated with UDCA, the short follow-up period, the limited number of total patients and lack of its being a randomized controlled study.

Conclusion

Since only a very small portion of patients develop symptomatic gallstones after gastric bypass, we recommend a selective and conventional approach together with ursodeoxycholic acid treatment rather than a prophylactic approach. Prospective randomized controlled studies in larger series are required to support these results.

Ethics committee approval was received for this study from the ethics committee of Tepecik Training and Research Hospital.

There is not the patient’s consent because of this study was restrospective, any personal information and document were shared.

Externally peer-reviewed.

Concept - M.K., M.G.; Design - M.K..; Data Collection and/or Processing - M.K., M.G.; Analysis and/or Interpretation - M.K., C.K.; Literature Review - M.K.; Writer - M.K., C.K.; Critical Review - M.K., M.G., C.K.

No conflict of interest was declared by the authors.

The authors declared that this study has received no financial support.

References

1. Schauer PR, Schirmer BD. The Surgical Management of Obesity. In: Brunicardi FC, editor. Schwartz’s Principles of Surgery. 8th ed. New York: The McGraw-Hill Companies; 2005.pp.997-1016.
2. Albrecht RJ, Pories WJ. Surgical intervention for the severely obese. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 149-172.
3. Iglezias Brando de Oliveira C, Adami Chaim E, da Silva BB. Impact of rapid weight reduction on risk of cholelithiasis after bariatric surgery. Obes Surg 2003; 13: 625-628.
4. Jonas E, Marsk R, Rasmussen F, Freedman J. Incidence of postoperative gallstone disease after antiobesity surgery: population-based study from Sweden. Surg Obes Relat Dis 2010; 6: 54-58.
5. Fuller W, Rasmussen JJ, Ghosh J, Ali MR. Is routine cholecystectomy indicated for asymptomatic cholelithiasis in patients undergoing gastric bypass? Obes Surg 2007; 17: 747-751.
6. Nougou A, Suter M. Almost routine prophylactic cholecystectomy during laparoscopic gastric bypass is safe. Obes Surg 2008; 18: 535-539.
7. Guadalajara H, Sanz Baro R, Pascual I, Blesa I, Rotundo GS, Lopez JM, et al. Is prophylactic cholecystectomy useful in obese patients undergoing gastric bypass? Obes Surg 2006; 16: 883-885.
8. Fobi M, Lee H, IgveD, Felahy B, James E, Stanczyk M, et al. Prophylactic cholecystectomy with gastric bypass operation: Incidence of gallbladder disease. Obes Surg 2002; 12: 350-353.
9. Taylor J, Leitman IM, Horowitz M. Is routine cholecystectomy necessary at the time of Roux-en-y gastric bypass? Obes Surg 2006; 16: 759-61.
10. Escalona A, Boza C, Munoz R, Perz G, RayoS, Crovari F, et al. Routine preoperative ultrasonography and selective cholecystectomy in laparoscopic Roux-en-y gastric bypass. Why not? Obes Surg 2008; 18: 47-51.
11. Uy MC, Talingdan-Te MC, Espinosa WZ, Daez ML, Ong JP. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: A meta-analysis. Obes Surg 2008; 18: 1532-1538.
12. Mason EE, Renquist KE. Gallbladder management in obesity surgery. Obes Surg 2002; 12: 222-229.
13. Faloon WW. Hepatobiliary effects of obesity and weight-reducing surgery. Semin Liver Dis 1988; 8: 229-236.
14. Marzio L, Capone F, Neri M, Mezzetti A, De Angelis C, Cuccurullo F. Gallbladder kinetics in obese patients. Effect of a regular meal and a low-calorie. Dig Dis Sci 1988; 33: 4-9.
15. Farrell TM, Haggerty SP, Overby DW, Kohn GB, Richardson WS, Fanelli RD. Clinical application of laparoscopic bariatric surgery: an evidence-based review. Surg Endosc 2009; 23: 930-949.
16. Aidonopoulos AP, Papavramidis ST, Zaraboukas TG, Habib HW, Pothoulakis IG. Gallbladder findings after cholecystectomy in morbidly obese patients. Obes Surg 1994; 4: 8-12.
17. Schmidt JH, Hocking MP, Rout WR, Woodward ER. The case for prophylactic cholecystectomy concomitant with gastric restriction for morbid obesity. Am Surg 1988; 54: 269-272.
18. Dittrick GW, Thompson JS, Campos D, Bremers D, Sudan D. Gallbladder pathology in morbid obesity. Obes Surg 2005; 15: 238-242.
19. Liem RK, Niloff PH. Prophylactic cholecystectomy with open gastric bypass operation. Obes Surg 2004; 14: 763-765.
20. Shiffman ML, Sugerman HJ, Kellum JM, Brewer WH, Moore EW. Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol 1991; 86: 1000-1005.
21. Patel KR, White SC, Tejirian T, Han SH, Russell D, Vira D, et al. Gallbladder management during laparoscopic Roux-en-Y gastric bypass surgery: routine preoperative screening for gallstones and postoperative prophylactic medical treatment are not necessary. Am Surg 2006; 72: 857-861.
22. Williams CN, Gowan R, Perey BJ. A double-blind placebo-controlled trial of ursodeoxycholic acid in the prevention of gallstones after vertical banded gastroplasty. Obes Surg 1993; 3: 257-259.
23. Sugerman HJ, Brever WH, Shiffman ML, Brolin RE, Fobi MA, Linner JH, et al. A multicenter placebo controlled randomized double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric by- pass induced rapid weight loss. Am J Surg 1995; 169: 91-97.
24. Miller K, Hell E, Lang B, Lengauer E. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial. Ann Surg 2003; 238: 697-702.